chemie.pr-2008 April 26 | Aktuelle News aus Deutschland und der Welt
Roche's R1626, First-in-Class Hepatitis C Polymerase Inhibitor, Demonstrates Impressive End-of-Treatment Response in Phase IIa Study
Roche's R1626, First-in-Class Hepatitis C Polymerase Inhibitor, Demonstrates Impressive End-of-Treatment Response in Phase IIa Study
26.04.2008 18:40:06
Roche Pharmaceuticals: Basel, Switzerland (ots/PRNewswire) - - R1626 Also Shows a High Barrier to the Development of Resistance Roche's investigational treatment for hepatitis C, R1626, has shown an impressive end-of-treatment response rate when given in ...
Lesen Sie hier weiter... |
Drucken |
PDF
Ähnliche Artikel
- European Approval for Roche's Pegasys Personalises Treatment for a Subgroup of Hepatitis C Patients: Chance for Cure With Only Four Months of Treatment
- Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
- First Pivotal Trials Begin for Boehringer Ingelheim's Novel Triple Angiokinase Inhibitor Vargatef(TM) (BIBF 1120)
- New Pegasys Data Show Hepatitis B Patients Achieve Highly Positive Treatment Response That Comes as Close to a Cure as Possible
- VELCADE(R) (bortezomib) Findings Reinforce Efficacy and Survival Across Multiple Patient Populations
- European Commission Approval of New Indication for Roche's Pegasys(R) (peginterferon alfa-2a) Offers Hepatitis C Patients a Second Chance for a Cure
- European Medicines Agency (EMEA) Approves Relistor(TM) The First-in-Class Treatment of Opioid-Induced Constipation (OIC) in Advanced-Illness Patients
- New Study Shows That Pegasys Regimen Provides Higher Cure Rates for Hepatitis C Patients
- Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs
- Tibotec Begins Enrollment in Europe for Phase III Trial of Telaprevir in HCV Patients who Failed Prior Treatment
Mitsubishi Plastics stellt X-BARRIER[TM] vor / Die wirksamste ...
Roche's R1626, First-in-Class Hepatitis C Polymerase Inhibitor, Demonstrates Impressive End-of-Treatment Response in Phase IIa Study
Bankkaufmann - News
Roche's R1626, First-in-Class Hepatitis C Polymerase Inhibitor, Demonstrates Impressive End-of-Treatment Response in Phase IIa Study
ots.at: das APA-OTS-Portal für multimediale Presseaussendungen
Roche's R1626, First-in-Class Hepatitis C Polymerase Inhibitor, Demonstrates Impressive.End-of-Treatment Response in Phase IIa Study = 26.04.2008 / 18:18
Roche s R1626, First-in-Class Hepatitis C Polymerase Inhibitor ...
Roche s R1626, First-in-Class Hepatitis C Polymerase Inhibitor, Demonstrates Impressive End-of-Treatment Response in Phase IIa Study